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Background: Adjuvant cisplatin-based chemotherapy has been shown 
to improve survival in patients with resected NSCLC; however, compli-
ance with chemotherapy has been problematic. Carboplatin (C) is better 
tolerated than cisplatin, and carboplatin-based treatment may improve 
adjuvant chemotherapy compliance. C/D is a commonly used in the 
treatment of advanced NSCLC with an acceptable toxicity proﬁle.
Methods: Pts with resected NSCLC with a good functional status, pre-
served renal, hepatic, and bone marrow function were enrolled. Thera-
py was initiated therapy at least 2 weeks from surgery, and consisted of 
4 cycles C (area under curve of 6), and docetaxel (D) 75 mg/m2 every 3 
weeks. The primary end-point was the feasibility of delivering C/D. An 
“adequate exposure” was deﬁned as receiving 4 cycles of C/D within 
12 weeks of initiating therapy. A sample size of 72 pts provided 88% 
power to detect a true adequate exposure of rate of at least 80%.
Results: 75 patients have been enrolled on the protocol, and 71 patients 
have completed therapy, 3 patients withdrew consent prior to initiating 
therapy, 1 patient is currently receiving therapy. Pt demographic data 
are: median age 65 (range 47-84); gender: female 33%, male 67%; 
race: white 86%, African American 10%, Asian 1%, Latino 1%, and 
unknown ethnicity 1%; performance status 0 (39%) 1 (60%), 2 (1%). 
The stage distribution was: stage I (40%), stage II (33%), stage IIIA 
(25%), and stage IIIB (1%). The histology distribution: adenocarcino-
ma (44%), squamous cell (42%), large cell (4%), and undifferentiated 
NSCLC (10%). 
To date 51/71 (72%) of pts completed 4 cycles within 12 weeks, and 
56/71 (79%) pts completed 4 cycles within 14 weeks. Eleven pts have 
had dose reduction of the D, and 41/71 (56%) patients completed 4 
cycles at full dose within 12 weeks, 45/71 (63%) completed 4 cycles at 
full dose within 14 weeks. The reasons for discontinuing therapy: ad-
verse events (n=5), disease progression (n=3), withdrew from treatment 
(n=5) complications of other medical condition (n=2). No treatment 
related deaths were observed, and the primary toxicities were hemato-
logic. The most common toxicities were grade 4 neutropenia (43%), 
and febrile neutropenia (11%). Treatment with growth colony stimulat-
ing factors was not required by the protocol.
Conclusions: Preliminary results indicate that adjuvant therapy with 
CD was well tolerated with the majority of received 4 cycles of therapy 
within 12 weeks.
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Background: The number of elderly patients (p) with cancer continues 
to increase. Approximately two-thirds of p diagnosed with non-small 
cell lung cancer are >65 years (y), and nearly 50% are >70 y. The aim 
of our study was to discern whether clinical characteristics, toxicity, 
response rate, treatment and survival are different in p <70 y vs ≥70 y. 
Methods: We reviewed data on p characteristics, stage, histology, 
response and survival in 6 SLCG clinical trials of different doublet 
combinations from 2000 to 2005. 
Results: Of 1653 p included, only 280 p (17%) were >70 y. No sig-
niﬁcant differences were found between the two groups with respect to 
gender, stage, response rate or histology. However, a higher frequency 
of squamous cell carcinoma was found in p >70 y. No differences were 
found in median number of cycles administered. The only signiﬁcant 
difference was found in the higher frequency of grade 3-4 neutropenia 
among p >70 y (Table). 
Conclusions: p >70 y were a small percentage of all p included in 
these clinical trials. However, outcome and toxicities were similar in 
p >70 y vs < 70y, and “ﬁt” elderly p can be treated with standard dou-
blets. Further research is warranted on genetic differences for custom-
izing treatment in this population. 
Age Cohort <70yrs >70yrs P
Gr>3/4 toxicity (95%CI) 
Febrile Neutropenia 5% (4-7) 8% (5-13) 0.11
Neutropenia 20% (17.7-22.9) 26% (20-32) 0.05
Anemia 5% (4-7) 4.8% (2-9) 0.63
Thrombocytopenia 4% (2.8-5.5) 3.4% (1.4-6.8) 0.67
Nausea/vomiting 16.5 (14-19) 13.5 (9-18) 0.27
Outcome 
TTP (mo) 4.4 (0-33.7) 4.5 (0-24.9) 0.49
MS (mo) 7.6 (0.1-47) 7.5 (0.1-30)  
1 yr OS (%) 35% 42%  
2 yr OS (%) 14% 16%  
